Home > Boards > US Listed > Biotechs > ArQule Inc. (ARQL)

Congrats on the entry point!! That is a

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Couch  Member Profile
Member Level 
Followed By 281
Posts 33,124
Boards Moderated 0
Alias Born 07/06/12
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 5:35:17 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/14/2020 12:20:35 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 5:03:56 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 12:05:45 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2020 1:43:10 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 11:29:38 AM
Termination of Registration of a Class of Security Under Section 12(g) (15-12g) Edgar (US Regulatory) - 1/27/2020 1:55:27 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/21/2020 6:00:55 AM
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm PR Newswire (US) - 1/6/2020 11:07:00 AM
WeissLaw LLP Investigates ArQule, Inc. PR Newswire (US) - 12/12/2019 3:49:00 PM
Merck, Sanofi Push To Add Cancer Drugs -- WSJ Dow Jones News - 12/10/2019 3:02:00 AM
Big Drugmakers Push Deeper Into Cancer Treatment -- 4th Update Dow Jones News - 12/9/2019 7:16:00 PM
Big Drugmakers Push Deeper Into Cancer Treatment -- 3rd Update Dow Jones News - 12/9/2019 4:37:00 PM
U.S. Stocks Slip as Trade War Weighs on Chinese Exports Dow Jones News - 12/9/2019 3:12:00 PM
Big Drugmakers Push Deeper Into Cancer Treatment -- 2nd Update Dow Jones News - 12/9/2019 2:33:00 PM
Merck to Buy ArQule for $2.7 Billion -- Update Dow Jones News - 12/9/2019 11:13:00 AM
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology... Business Wire - 12/9/2019 8:05:00 AM
(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price? PR Newswire (US) - 12/9/2019 7:37:00 AM
Merck to Buy ArQule for $2.7 Billion, or $20/Share Dow Jones News - 12/9/2019 7:26:00 AM
Merck to Acquire ArQule, Advancing Leadership in Oncology Business Wire - 12/9/2019 6:45:00 AM
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual ... Business Wire - 11/25/2019 7:00:00 AM
ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019 Business Wire - 11/13/2019 7:00:00 AM
ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversi... Business Wire - 11/6/2019 9:05:00 AM
Couch Member Level  Monday, 12/09/19 02:48:31 PM
Re: NSX post# 332
Post # of 369 
Congrats on the entry point!! That is a sizable gain....I'm in at $6.98.......any thoughts on what you do with your shares moving forward?

Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist